CIK 0001689375
- Accelerated filer
- Smaller reporting company
- Emerging growth company
Entrada Therapeutics, Inc.
Sign in to watch- Ticker
- TRDA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 813983399
- Phone
- +1 857-305-1825
- Business address
- ONE DESIGN CENTER PLACE, SUITE 17-500, BOSTON, MA, 02210
- Former names
- CycloPorters, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $7,200,939
- in 8 filings
Net −$7,200,939. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 21 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-05-18 | BAKER BROS. ADVISORS LP 10% owner | Purchase | +692 | $5.92 | $4K | 4,391,686 |
| 2022-05-18 | BAKER BROS. ADVISORS LP 10% owner | Purchase | +3,654 | $6.00 | $22K | 354,674 |
| 2022-05-18 | BAKER BROS. ADVISORS LP 10% owner | Purchase | +30,003 | $6.00 | $180K | 4,421,689 |
| 2022-05-17 | BAKER BROS. ADVISORS LP 10% owner | Purchase | +2,010 | $6.13 | $12K | 350,936 |
| 2022-05-17 | BAKER BROS. ADVISORS LP 10% owner | Purchase | +16,501 | $6.13 | $101K | 4,390,994 |
| 2022-05-16 | BAKER BROS. ADVISORS LP 10% owner | Purchase | +2,063 | $5.83 | $12K | 348,926 |
| 2022-05-16 | BAKER BROS. ADVISORS LP 10% owner | Purchase | +16,937 | $5.83 | $99K | 4,374,493 |
| 2022-03-01 | Dowden Nathan J Chief Operating Officer | Grant or award | +11,263 | 72,607 | ||
| 2022-03-01 | Dowden Nathan J Chief Operating Officer | Grant or award · Stock Option (Right to Buy) | +67,575 | 67,575 | ||
| 2022-03-01 | Sethuraman Natarajan Chief Scientific Officer | Grant or award | +11,588 | 156,350 | ||
| 2022-03-01 | Sethuraman Natarajan Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +69,525 | 69,525 | ||
| 2022-03-01 | KREHER NERISSA Chief Medical Officer | Grant or award | +10,344 | 15,544 | ||
| 2022-03-01 | KREHER NERISSA Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +62,063 | 62,063 | ||
| 2022-03-01 | WENTWORTH KORY JAMES Chief Financial Officer | Grant or award | +11,006 | 20,541 | ||
| 2022-03-01 | WENTWORTH KORY JAMES Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +66,038 | 66,038 | ||
| 2022-03-01 | Doshi Dipal President and CEO | Grant or award | +30,250 | 214,710 | ||
| 2022-03-01 | Doshi Dipal President and CEO | Grant or award · Stock Option (Right to Buy) | +181,500 | 181,500 |
Page 26 of 26 · 517 trades